SFM
NERV icon

Sphera Funds Management’s Minerva Neurosciences NERV Stock Holding History

Sphera Funds Management’s Portfolio NERV Stock Details NERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-21,045
Closed -$1.01M – 101
2020
Q1 		$1.01M Sell
21,045
-85,830
-80% -$5.18M 0.13% 62
2019
Q4 		$6.08M Buy
106,875
+11,623
+12% +$513K 0.5% 45
2019
Q3 		$5.91M Buy
95,252
+1,250
+1% +$70.8K 0.91% 33
2019
Q2 		$4.23M Buy
94,002
+13,750
+17% +$688K 0.58% 54
2019
Q1 		$5.05M Sell
80,252
-17,500
-18% -$1.05M 0.46% 50
2018
Q4 		$5.27M Sell
97,752
-7,547
-7% -$552K 0.59% 41
2018
Q3 		$10.6M Buy
105,299
+2,784
+3% +$209K 1.21% 17
2018
Q2 		$6.77M Buy
102,515
+5,640
+6% +$343K 0.93% 26
2018
Q1 		$4.84M Hold
96,875
– – 0.74% 43
2017
Q4 		$4.69M Buy
96,875
+18,750
+24% +$930K 0.55% 46
2017
Q3 		$4.75M Buy
78,125
+18,904
+32% +$1.08M 0.68% 40
2017
Q2 		$4.19M Buy
+59,221
New +$3.83M 0.71% 38

Other funds holding NERV

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Sphera Funds Management's NERV Position: Q2 2020 in Review

Sphera Funds Management sold out of Minerva Neurosciences (NERV) in Q2 2020, closing a stake of 21,045 shares — an estimated $1.01M sold.

Sphera Funds Management first reported a position in NERV in Q2 2017 and held it in 12 quarters. The position peaked at $10.6M in Q3 2018. 80 funds tracked by Wall St. Rank hold NERV as of Q2 2020.

  • Sphera Funds Management reported no remaining Minerva Neurosciences position as of Q2 2020 after selling out during the quarter.
  • Sphera Funds Management sold 21,045 Minerva Neurosciences shares in Q2 2020, an estimated $1.01M.
  • Sphera Funds Management first reported a position in Minerva Neurosciences in Q2 2017 and held it in 12 quarters.
  • Sphera Funds Management's Minerva Neurosciences position peaked at $10.6M in Q3 2018.
  • 80 funds tracked by Wall St. Rank held Minerva Neurosciences as of Q2 2020.

Based on Sphera Funds Management's 13F filing for Q2 2020, filed 13 Aug 2020.